The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Incannex Healthcare (IHL) spends the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies
  • Net cash outflows were $2.1 million with cash inflows at $133,000
  • The company ended the period with $9.1 million in cash
  • The company currently has six pending US food and drug administration (FDA) programs that have all progressed
  • On the market, Incannex was trading in the grey at 25 cents per share

Incannex Healthcare (IHL) has spent the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies.

The company ended the period with over $9.1 million in the bank. Net cash outflows were $2.1 million, which mostly included research and development expenditures.

Cash inflows were $133,000, which was associated with the sale of unregistered cannabinoid oils during the quarter.

The company currently has six US food and drug administration (FDA) programs.

Psilocybin-assisted psychotherapy for generalised anxiety disorder (Psi-GAD)

Incannex’s Psi-GAD therapy combines psilocybin with psychological support that has been specifically designed for patients diagnosed with generalised anxiety disorder

The company is now in the process of coordinating two clinical trials for Psi-GAD as part of the clinical development program aimed at receiving FDA approval.

Recruitment of therapists for these trials is nearly completed with the therapist training program to commence in the third quarter of 2021.

IHL-42X for obstructive sleep apnoea

During the quarter, Incannex engaged with the University of Western Australia for Sleep Science as an additional site to its clinical trial.

The trial investigating the effect of IHL-42X on the apnoea hypopnea index in adults diagnosed with obstructive sleep apnoea.

Results of the trial will be available once all subjects have completed treatment and the clinical study report is finalised, which is expected by the end of the year.

IHL-675A for lung inflammation, rheumatoid arthritis, and inflammatory bowel disease

In the fourth quarter, Incannex held its pre-investigational new drug application with the FDA.

From this meeting, the company expanded its development program to assess the potential for IHL-675A to become a multi-use pharmaceutical drug applicable to inflammatory lung conditions rheumatoid arthritis and inflammatory bowel disease.

Incannex commenced its phase one human clinical trial in July to assess the safety of IHL-675A soft gel capsules.

IHL-216A for concussion and traumatic brain injuries

Incannex also developed a clinical trial for its IHL-216A treatment with Vectura, a state-of-the-art contract development and manufacturing organisation.

IHL-216A is a combination drug that combines CBD with any volatile anaesthetic agent, including isoflurane. It has been created to be administered soon after head trauma to reduce secondary brain injuries that lead to neurological deficits.

On the market, Incannex was trading in the grey at 25 cents per share at 11:46 am AEST.

IHL by the numbers
More From The Market Online

Universal Biosensors surges 60% on FDA approval for Class II device

Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical…

Vitura joint venture prescribes shrooms for therapeutic use in Australian-first

In an Australian-first pharmaceutical achievement, Vitura Health Limited has announced the first ever shipment of 'shrooms'…

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…